

Letters

RESEARCH LETTER

Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results

Some patients who have recovered from coronavirus disease 2019 (COVID-19) with documented negative real-time polymerase chain reaction (RT-PCR) results at the time of recovery have had subsequent positive RT-PCR test results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)^{1,2} in the absence of

any symptoms suggestive of new infection.³ It is unknown whether such patients are infectious and whether they should be quarantined. Real-time PCR is not a viral culture and does not allow determination of whether the virus is viable and transmissible. We investigated RT-PCR retested positive nasal/oropharyngeal swab (NOS) samples from recovered patients with COVID-19 with prior negative results for the presence of replicative SARS-CoV-2 RNA.⁴



Editor's Note



Supplemental content

Table. Testing Results for NOS Samples Obtained at COVID-19 Diagnosis or After COVID-19 Recovery in 32 Study Patients^a

	COVID-19 samples tested												
	Diagnosis				Recovery								
Sample	Genomic RNA (C _T value)			Subgenomic RNA (C _T value)	Genomic RNA (C _T value)			Subgenomic (C _T value)	RNA load, copies/mL	Serology (positive or negative result)		Days of recovery sampling since diagnosis	
Sample No.	E gene	RdRP gene	N gene	E gene	E gene	RdRP gene	N gene	E gene	N gene	IgG	IgA		
1	31.6	31.3	31.2	34.5	29.3	30.7	31.2	39.1	1.2 × 10 ⁴	Positive	Positive	39	
2	27.0	26.9	30.0	36.0	30.0	30.5	31.2		8.9 × 10 ³	Positive	Positive	31	
3	19.3	20.8	22.1	35.2	31.5	34.7	32.8		3.3 × 10 ³	Positive	Negative	44	
4	21.6	22.0	22.9	36.4	31.8	31.4	32.3		5.5 × 10 ³	Positive	Positive	34	
5	30.0	32.8	38.1	30.2	31.8	34.3	34.5		3.2 × 10 ³	Positive	Positive	62	
6	20.8	20.9	22.3	37.3	32.2	32.8	34.1		5.3 × 10 ³	Positive	Positive	37	
7	27.3	29.9	31.3	36.9	32.3	30.9	32.7		6.4 × 10 ³	Positive	Positive	39	
8	26.9	27.0	31.2	38.1	35.0	34.4	36.1		4.0 × 10 ²	Positive	Positive	71	
9	22.5	23.7	24.9	31.0	38.8	33.6	33.9		2.6 × 10 ³	Negative	Negative	42	
10	21.3	21.4	28.9	38.9		32.2	33.4		1.2 × 10 ⁴	Positive	Positive	56	
11	26.6	26.9	28.1	33.0		32.8	33.2		1.3 × 10 ⁴	Positive	Positive	54	
12	22.8	24.2	25.3	31.0		34.2	33.7		6.9 × 10 ³	Positive	Positive	55	
13	25.8	25.8	26.1	39.8	NA	34.8	39.1		3.0 × 10 ²	Positive	Positive	36	
14	20.8	20.4	21.1	32.0		35.0	35.1		1.9 × 10 ³	Positive	Positive	56	
15	29.4	30.1	32.2	37.0		36.5	39.2		3.2 × 10 ³	Positive	Positive	36	
16	27.9	29.1	31.1	32.0		38.1	39.3		1.6 × 10 ¹	Positive	Positive	77	
17	30.6	29.9	31.8	32.1			35.7	NA	5.4 × 10 ³	Positive	Positive	53	
18	28.5	29.1	30.8	36.8			36.8		2.9 × 10 ³	Positive	Positive	43	
19	26.9	22.2	26.1	30.1			37.5		1.1 × 10 ³	Positive	Positive	36	
20	25.7	25.2	28.9	38.0			37.9		2.6 × 10 ³	Positive	Positive	48	
21	27.0	29.0	30.2	32.3			38.1		1.9 × 10 ³	Positive	Positive	41	
22	28.5	29.4	30.0	32.3			38.4		4.9 × 10 ¹	Positive	Negative	76	
23	27.1	28.6	29.3	36.1			38.9		4.5 × 10 ²	Positive	Positive	29	
24	25.4	22.9	24.1	34.8			39.0		5.6 × 10 ¹	Positive	Positive	70	
25	28.7	29.5	31.4	37.3	NA		39.1		5.4 × 10 ³	Negative	Positive	46	
26	27.1	27.7	29.2	37.1			39.1		1.9 × 10 ³	Positive	Positive	34	
27	26.7	27.7	29.6	39.2			39.2		2.0 × 10 ³	Positive	Positive	45	
28	17.1	19.1	19.9	33.0			39.2		8.5 × 10 ²	Positive	Positive	40	
29	27.0	28.9	30.0	32.1			39.3		5.0 × 10 ¹	Positive	Positive	56	
30	22.9	23.8	25.8	37.1			39.4		1.6 × 10 ²	Positive	Positive	55	
31	28.6	30.4	30.9	33.0			39.6		5.3 × 10 ²	Positive	Positive	61	
32	29.1	28.0	30.9	36.2			39.8		3.4 × 10 ²	Positive	Positive	53	

Abbreviations: COVID-19, coronavirus disease 2019; C_T, cycle threshold; E gene, envelope gene; NA, not applicable; N gene, nucleocapsid gene; RdRP, RNA-dependent RNA polymerase; RT-PCR, real-time polymerase chain reaction.

^a For RT-PCR testing, the Seegene Allplex 2019-nCoV and Clonit Quanty COVID-19 assays were used for total RNA detection and quantification, respectively, whereas replicative (E gene) RNA was detected by an in-house RT-PCR assay.⁴ Results were expressed as C_T values (<40 for positive detection) or quantified as RNA (N gene) copies per mL. NA indicates the absence of positive detection for the indicated gene. For serological testing, SARS-CoV-2 IgG/IgA Euroimmun enzyme-linked immunoassays were used, and positive and negative results were assessed using the 1.1 or greater or less than 1.1 times the manufacturer's cutoffs as reference IgG/IgA values, respectively.

Methods | We studied 176 recovered patients with COVID-19 who were admitted to the postacute outpatient service of our institution (Rome, Italy) from April 21 to June 18, 2020, for COVID-19 follow-up.^{5,6} Before that, patients had discontinued isolation according to current criteria,⁵ which require no fever for 3 consecutive days, improvement in other symptoms, and 2 negative RT-PCR results for SARS-CoV-2 RNA 24 hours apart.

Nasal/oropharyngeal swab samples from patients at follow-up were analyzed for total (genomic) and replicative (subgenomic) SARS-CoV-2 RNA using RT-PCR assays (eMethods in the [Supplement](#)). For patients with positive results for total RNA, samples previously obtained at the time of COVID-19 diagnosis and kept at -112 °F until testing were also tested for replicative RNA. Serological testing was performed for SARS-CoV-2 IgG/IgA detection (eMethods in the [Supplement](#)). The ethics committee of the Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy) approved the study, and written informed consent was obtained from each patient.

Results | As shown in the [Table](#),⁴ 32 of 176 NOS samples (18.2%) tested positive for total SARS-CoV-2 RNA, with viral loads ranging from 1.6×10^4 to 1.3×10^4 SARS-CoV-2 RNA copies per mL. One of the 32 samples (3.1%) had replicative SARS-CoV-2 RNA. Samples from the 32 patients at the time of COVID-19 diagnosis were also tested and, expectedly, had replicative SARS-CoV-2 RNA. All but 1 of 32 patients had a positive serology result against SARS-CoV-2 ([Table](#)), as well as 139 of remaining 144 patients (data not shown), at COVID-19 follow-up. The patient who tested serologically negative was not the one with a positive test result for replicative SARS-CoV-2 RNA. The mean (SD) time from COVID-19 diagnosis to follow-up was 48.6 (13.1) days in 32 patients ([Table](#)) and 57.7 (16.9) days in 144 patients (data not shown).

Discussion | Similar to that reported elsewhere,² 18% of patients with COVID-19 in our institution became RT-PCR positive for SARS-CoV-2 RNA after clinical recovery and previous negative results.⁵ As positivity in the patients was suggestive, but not necessarily a reflection, of viral carriage, we used replicative SARS-CoV-2 RNA detection as a proxy for virus replication in culture.⁴

Only 1 of 32 patients retesting positive had replicating virus in the NOS sample, suggesting either recurrent infection or reinfection, which is impossible to separate because no whole-genome sequencing and phylogenetic analyses were performed.³ The patient retested positive 16 days after COVID-19 recovery (ie, 39 days from COVID-19 diagnosis) and was symptomatic. The patient was an older adult with hypertension, diabetes, and cardiovascular disease but no evidence of close contacts with people with SARS-CoV-2 infection or persons who became RT-PCR positive. In the 31 remaining patients (who were asymptomatic), their positive result likely represented either recurrent or resolving infection, but in either case, they were unlikely to be infectious. The limitations of our study are the lack of data from viral cultures or whole-genome sequencing analysis and the small sample size.

Conclusions | This study highlights that many patients who recovered from COVID-19 may be still positive (albeit at lower levels) for SARS-CoV-2 RNA, but only a minority of the pa-

tients may carry a replicating SARS-CoV-2 in the respiratory tract. Further studies are needed to verify whether such patients can transmit the virus.

Flora Marzia Liotti, PhD
Giulia Menchinelli, PhD
Simona Marchetti, BSc
Brunella Posteraro, PhD
Francesco Landi, MD
Maurizio Sanguinetti, MD
Paola Cattani, MD

Author Affiliations: Dipartimento di Scienze Biologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy (Liotti, Menchinelli, Posteraro, Sanguinetti, Cattani); Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (Liotti, Menchinelli, Sanguinetti, Cattani); Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (Posteraro); Dipartimento di Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (Landi).

Accepted for Publication: October 25, 2020.

Published Online: November 12, 2020. doi:[10.1001/jamainternmed.2020.7570](https://doi.org/10.1001/jamainternmed.2020.7570)

Corresponding Author: Brunella Posteraro, PhD, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy (brunella.posteraro@unicatt.it).

Author Contributions: Drs Sanguinetti and Cattani had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Liotti and Menchinelli contributed equally to the study. Drs Sanguinetti and Cattani contributed equally as senior authors.

Concept and design: Liotti, Posteraro, Landi, Sanguinetti, Cattani.

Acquisition, analysis, or interpretation of data: Liotti, Menchinelli, Marchetti, Posteraro, Sanguinetti, Cattani.

Drafting of the manuscript: Liotti, Menchinelli, Posteraro, Sanguinetti, Cattani.

Critical revision of the manuscript for important intellectual content: Liotti, Marchetti, Landi, Sanguinetti, Cattani.

Statistical analysis: Menchinelli.

Obtained funding: Sanguinetti.

Supervision: Posteraro, Landi.

Other: Liotti.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was funded by donations from Reale Group and Fondazione Valentino Garavani & Giancarlo Giammetti to support the COVID-19 research in our institution.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Franziska Lohmeyer, PhD (Scientific Direction, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy) for English revision of the manuscript. She was not compensated for her contributions.

1. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. *JAMA*. 2020;323(15):1502-1503. doi:[10.1001/jama.2020.2783](https://doi.org/10.1001/jama.2020.2783)

2. Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection? *J Med Virol*. 2020;1-3. doi:[10.1002/jmv.26114](https://doi.org/10.1002/jmv.26114)

3. Alvarez-Moreno CA, Rodríguez-Morales AJ. Testing dilemmas: post negative, positive SARS-CoV-2 RT-PCR—is it a reinfection? *Travel Med Infect Dis*. 2020;35: 101743. doi:[10.1016/j.tmaid.2020.101743](https://doi.org/10.1016/j.tmaid.2020.101743)

4. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581(7809):465-469. doi:[10.1038/s41586-020-2196-x](https://doi.org/10.1038/s41586-020-2196-x)

5. Carfi A, Bernabei R, Landi F; for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *JAMA*. 2020;324(6):603-605. doi:[10.1001/jama.2020.12603](https://doi.org/10.1001/jama.2020.12603)

6. Gemelli Against COVID-19 Post-Acute Care Study Group. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. *Aging Clin Exp Res*. 2020;32(8): 1613-1620.